Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CTSG | P08311 | 1/20 | 0.40 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6758441 | 1.00 | ATM (0.46) | ATMELANECYP2C19KMT2APOLB | |
| SCHEMBL6758440 | 1.00 | ATM (0.46) | ATMELANECYP2C19KMT2APOLB | |
| SCHEMBL6758456 | 0.92 | ATM (0.43) | ATMELANECYP2C19KMT2APOLB | |
| SCHEMBL6758466 | 0.92 | ATM (0.43) | ATMELANECYP2C19KMT2APOLB | |
| SCHEMBL6758461 | 0.92 | ATM (0.43) | ATMELANECYP2C19KMT2APOLB | |
| SCHEMBL6481590 | 0.91 | CYP19A1 (0.43) | ATMELANECYP2C19KMT2APOLB | |
| SCHEMBL6758108 | 0.91 | ATM (0.42) | ATMELANECYP2C19KMT2APOLB | |
| SCHEMBL6481596 | 0.91 | CYP19A1 (0.43) | ATMELANECYP2C19KMT2APOLB | |
| SCHEMBL6759045 | 0.91 | ATM (0.42) | ATMELANECYP2C19KMT2APOLB | |
| SCHEMBL4393575 | 0.91 | ATM (0.42) | ATMELANECYP2C19KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0903353-B1 | Imidazolidine derivates, their preparation and use, and pharmaceutical compositions containing them | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-11-25 | — | — | EP | disclosed |
| EP-0903353-B1 | Imidazolidine derivates, their preparation and use, and pharmaceutical compositions containing them | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-11-25 | — | — | EP | disclosed |
| US-6759424-B2 | 2,5-DIOXOIMIDAZOLIDINE OR 2-THIO-5-OXOIMIDAZOLIDINE DERIVATIVES SUITABLE FOR THE THERAPY AND PROPHYLAXIS OF INFLAMMATORY DISORDERS, FOR EXAMPLE OF RHEUMATOID ARTHRITIS, OR OF ALLERGIC DISORDER | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-06 | — | — | US | disclosed |
| US-20030125565-A1 | Imidazolidine derivatives, their preparation, their use, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-07-03 | — | — | US | disclosed |
| US-6423712-B1 | 2,4-Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-23 | — | — | US | disclosed |
| EP-0903353-A1 | Imidazolidine derivates, their preparation and use, and pharmaceutical compositions containing them | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125565-A1 | Imidazolidine derivatives, their preparation, their use, and pharmaceutical preparations comprising them | VCAM1, ITGA1, ITGA4 | ATM 4830/4885ELANE 258/4885CYP2C19 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.